Rimacalib is primarily investigated for its potential therapeutic applications in the treatment of cardiovascular diseases. It functions as a small molecule inhibitor targeting specific pathways involved in vascular calcification, a condition where calcium builds up in blood vessels, leading to reduced elasticity and increased risk of heart disease. By inhibiting these pathways, Rimacalib aims to prevent or reduce the progression of calcification, thereby improving vascular health. Its application is particularly relevant in managing conditions like atherosclerosis and chronic kidney disease, where vascular calcification is a common complication. Research is ongoing to evaluate its efficacy and safety in clinical settings, with the goal of developing it as a novel treatment option for patients at risk of or suffering from these conditions.